We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pfizer's CEO Ian Read to Step Down Next Year, COO to Succeed
Read MoreHide Full Article
Pfizer Inc. (PFE - Free Report) announced that chief executive officer (“CEO”), Ian Read, will step down from the post, beginning 2019. Ian will be succeeded by the company’s current chief operating officer (“COO”), Albert Bourla.
Read has served as the CEO of the company for eight years and has been the chairman of its board of directors since December 2011. He will serve as executive chairman of Pfizer’s board of directors from next year.
During Read’s term, Pfizer did well despite patent expiration of some of its blockbuster drugs. The company also received 30 FDA approvals in these eight years. Its share price also rose during the time and has outperformed the broader S&P 500.
Pfizer has also built a strong pipeline, which includes 15 candidates with blockbuster potential. These are expected to get approved by 2022. The company has formed strategic collaboration agreements with other pharma companies like Bristol-Myers Squibb (BMY - Free Report) for Eliquis and Japan based Astellas for Xtandi.
Read’s successor, Bourla also has a strong track record with more than 25 years of service at Pfizer. Prior to his appointment as COO on Jan 1, 2018, he led the company’s Innovative Health business, which recorded operational growth of 7% in revenues in 2017, and established the segment in emerging markets. Moreover, Pfizer’s oncology business tripled under his supervision in the past four years. We expect him to continue with his impressive performance going forward.
Talking about CEO transitions, we remind investors that Pfizer’s competitor Merck (MRK - Free Report) announced last week that it has amended its retirement policy, repealing the mandatory retirement age of 65 years for a CEO. The amendment was done to retain its current CEO, Kenneth Frazier, beyond his term, which is scheduled to end in 2019.
Moreover, General Electric Company (GE - Free Report) also announced on Oct 1 that its current CEO and chairman, John Flannery, will be replaced by another board member, H. Lawrence Culp, Jr. The company has struggled so far this year. This more than a century-old company was removed from Dow Jones Industrial Average index in June. Investors expect the new CEO to help the company post a turnaround.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
Image: Bigstock
Pfizer's CEO Ian Read to Step Down Next Year, COO to Succeed
Pfizer Inc. (PFE - Free Report) announced that chief executive officer (“CEO”), Ian Read, will step down from the post, beginning 2019. Ian will be succeeded by the company’s current chief operating officer (“COO”), Albert Bourla.
Read has served as the CEO of the company for eight years and has been the chairman of its board of directors since December 2011. He will serve as executive chairman of Pfizer’s board of directors from next year.
During Read’s term, Pfizer did well despite patent expiration of some of its blockbuster drugs. The company also received 30 FDA approvals in these eight years. Its share price also rose during the time and has outperformed the broader S&P 500.
Pfizer has also built a strong pipeline, which includes 15 candidates with blockbuster potential. These are expected to get approved by 2022. The company has formed strategic collaboration agreements with other pharma companies like Bristol-Myers Squibb (BMY - Free Report) for Eliquis and Japan based Astellas for Xtandi.
Read’s successor, Bourla also has a strong track record with more than 25 years of service at Pfizer. Prior to his appointment as COO on Jan 1, 2018, he led the company’s Innovative Health business, which recorded operational growth of 7% in revenues in 2017, and established the segment in emerging markets. Moreover, Pfizer’s oncology business tripled under his supervision in the past four years. We expect him to continue with his impressive performance going forward.
Talking about CEO transitions, we remind investors that Pfizer’s competitor Merck (MRK - Free Report) announced last week that it has amended its retirement policy, repealing the mandatory retirement age of 65 years for a CEO. The amendment was done to retain its current CEO, Kenneth Frazier, beyond his term, which is scheduled to end in 2019.
Moreover, General Electric Company (GE - Free Report) also announced on Oct 1 that its current CEO and chairman, John Flannery, will be replaced by another board member, H. Lawrence Culp, Jr. The company has struggled so far this year. This more than a century-old company was removed from Dow Jones Industrial Average index in June. Investors expect the new CEO to help the company post a turnaround.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>